Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... – The severe flooding that devastated a wide swath ... if the bridges, roads and other infrastructure had been ... the University of Colorado Denver. , "People need to ... Kim, PhD, associate professor of structural engineering at the ... lead author the study. "There is an assumption that ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... today announced two presentations demonstrating that the extent ... proprietary cancer immunotherapeutic AE37 vaccine correlated with a ... AE37 cancer vaccine is being developed by the ... ). The presentations are being made at the ...
(Date:10/27/2014)... 2014 The “Molecular Diagnostic Market ... Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, ... - Global Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5
... PARI Respiratory Equipment,s,breath-enhanced nebulizer, the PARI ... L.P.,s new COPD medication, Perforomist Inhalation Solution,that ... subsidiary of Mylan Inc.,(NYSE: MYL ). ... indicated for,long-term, twice-daily maintenance treatment of bronchoconstriction ...
... WASHINGTON, D.C., October 9 Bavarian Nordic,the Danish-based ... of Health and Human Services (HHS) to,invoice an ... the recent,contract (RFP-3)* to manufacture and deliver 20 ... HHS approved the advance payment because Bavarian Nordic ...
... Patient-Safety ... Technology,eRx NOW(TM) Functionality Expanded to ... Physician Portal Lab Order and Results Capabilities, LYNDHURST, N.J. and ... leading provider of,diagnostic testing, information and services and a leading developer of,healthcare ...
Cached Biology Technology:PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 2PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 3PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday 4Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 2Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones 3Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI) 2Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI) 3Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI) 4Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI) 5
(Date:10/30/2014)... help reduce or reverse soil subsidence and reduce ... Sacramento-San Joaquin River Delta by Dartmouth College researchers ... one of the first to continually measure the ... cycle through wetlands, appears in the journal by ... Worldwide, agricultural drainage of organic soils has resulted ...
(Date:10/30/2014)... This news release is available in German . ... we as individuals prompt our fellow humans to behave ... to social dilemmas in game theory. Previous studies assumed ... large groups. Nonetheless, scientists from the Max Planck Institute ... us can exert an influence on the cooperative behaviour ...
(Date:10/30/2014)... State University researchers have developed a suite of technologies ... and humans, which has applications in everything from search ... , "We,ve developed a platform for computer-mediated communication between ... avenues for interpreting dogs, behavioral signals and sending them ... Roberts, an assistant professor of computer science at NC ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4New tech aims to improve communication between dogs and humans 2
... German . , , "Watch out, it,ll hurt for a ... they hear those words from their doctor. And, as soon as ... very clearly. "After such an experience it is enough to simply ... pain memory", knows Prof. Dr. Thomas Weiss from the Friedrich-Schiller-University Jena. ...
... toads, salamanders, and newtsare disappearing worldwide, but the stream ... This region is home to the largest diversity of ... here), and scientists want to understand what contributes to ... in the March 29, 2010 issue of the ...
... Bionic Vision Australia (BVA) today unveils their wide-view ... implanted into Australia,s first recipient of the technology. ... at the University of New South Wales and unveiled ... University of Melbourne, will deliver improved quality of life ...
Cached Biology News:Do words hurt? 2Young salamanders' movement over land helps stabilize populations 2Young salamanders' movement over land helps stabilize populations 3Bionic Vision Australia puts bionic eye in sight 2
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
... The LX80L is an extension of Parkers ... maintaining a compact cross-section. LX80L bolt hole patterns ... mount MX80 units and all accessory brackets to ... stage with travel to 750 mm , Accelerations ...
... PEP-005 is a synthetic peptide whose sequence is from the C-terminal end ... acid sequence extends from amino acids 429 to 448 of RAR*. ... - S - V - S - P - S - S ... - S - Q - S - P - L - L ...
... Rat Neural Stem Cell Kit with ... cells (NCSs) complete with optimized base medium ... and plate these unique cells generated from ... you need for a tissue-like mixture of ...
Biology Products: